High dose glucocorticoids (GC) are commonly used for the treatment of autoimmune diseases. The frequencies, occurrence day and dose-dependency for side eŠects may be diŠerent among the events such as diabetes mellitus, hyperlipidemia, infectious disease, osteoporosis, and peptic ulcer. We investigated GC-induced side eŠects in 68 patients treated with GC for autoimmune diseases. Initial dose of GC (prednisolone equivalent) was 0.67±0.35 mg/kg/d. Hypercholesterolemia (66％), hypertension (62％), insomnia (50％), hypertriglyceridemia (44％), excessive appetite (38％), hyperglycemia (18％), digestive symptom (16％), moon-shaped face (13％) and oral candidiasis (12％) were observed in 63 patients treated with GC. Hypercholesterolemia, excessive appetite, digestive symptom, moon-shaped face, and oral candidiasis were associated with the initial dose of prednisolone greater than 0.80 mg/kg/d. )] were developed after 33 60 days starting GC. Since the frequencies, dose-dependency and occurrence day were diŠerent among the side eŠects of GC, medical staŠs including physicians and pharmacists should pay attention such features of the events in the treatment of autoimmune diseases.
Value are presented as number of patients(％) or mean±S.D. a) Total cholesterol ＞220 mg/dl or addition or change medication, b) Systolic pressure ≧140 mmHg or diastolic pressure ≧90 mmHg or addition or change medication, c) Symptomatic or addition or change medication, d ) Triglyceride ＞150 mg/dl or addition or change medication, e) Fasting blood suger ＞100 mg/dl or casual blood suger ＞200 mg/dl or HbA1c ＞5.8％ or addition or change medication, f ) Addition or change medication, g) Number of patients/68 (total number of patients), h) Number while admission/number of patients, Signiˆcant diŠerences compared to the patients without each side eŠect.
Fig. 2. Occurrence Day and Number of Patients in Each GC
induced Side EŠect A: Side eŠects of which median occurrence day was less than 30 days after the initiation of GC administration. B: Side eŠects of which median occurrence day was longer than 30 days after the initiation of GC administration. 
